AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45 million milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC’s progression to registrational-stage development.
>$1.1 billion potential (development and sales-based)
Current Milestone
$45 million (Phase III initiation)
Royalties
Tiered double-digit on net sales
Strategic Context & Market Opportunity
Factor
Implication
Gastric Cancer Burden
5th most common cancer globally; 1M+ annual deaths; Claudin 18.2 expressed in ~40% of gastric/GEJ adenocarcinomas
HER2-Negative Gap
~60% of gastric cancers HER2-negative; no targeted first-line options beyond chemotherapy
Claudin 18.2 Validation
Zolbetuximab (Astellas) approved 2024 (mAb); ADC mechanism (sonesitatug) offers superior potency and bystander killing
AstraZeneca Oncology
Enhances GI cancer portfolio (Tagrisso, Imfinzi); leverages global commercial infrastructure
Milestone Timing
$45M payment validates Phase III commitment; additional milestones for regulatory approvals and sales thresholds
Competitive Landscape
Competitor
Product
Mechanism
Setting
Sonesitatug Differentiation
Astellas
Vyloy (zolbetuximab)
Claudin 18.2 mAb
1L gastric (approved 2024)
ADC payload vs. ADCC; potential for combination superiority
Amgen
AMG 199
Claudin 18.2/CD3 BiTE
Phase I
Later-stage development; established AstraZeneca infrastructure
Keymed/AZ
Sonesitatug vedotin
Claudin 18.2 ADC
Phase III (1L)
First-in-class ADC with capecitabine ± immunotherapy backbone
Development Outlook
Phase
Timeline
Objectives
Phase III (CLARITY-Gastric 02)
2026-2029
Overall survival primary endpoint; global enrollment (Asia, EU, U.S.)
Regulatory Filing
2029-2030
China NDA; U.S./EU BLA simultaneous submission
Combination Expansion
Ongoing
Rilvegostomig addition may support label differentiation vs. chemotherapy alone
Biomarker Strategy
2026+
Claudin 18.2 IHC companion diagnostic development and commercialization
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III enrollment timelines, regulatory pathways, and milestone achievement for sonesitatug vedotin. Actual results may differ due to competitive dynamics with zolbetuximab, gastric cancer trial execution risks, and manufacturing scale-up challenges.-Fineline Info & Tech
By Fineline Cube